June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, today announced that its NIVAHF device has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).

June 15, 2021 — A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of the heart than symptom-based testing, according to a study led by researchers at The Ohio State University Wexner Medical Center and College of Medicin

June 14, 2021 — Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly understood that they share common risk factors, including tobacco use, diet, blood pressure, and obesity.

June 14, 2021 — An advanced artificial intelligence technique known as deep learning can predict major adverse cardiac events more accurately than current standard imaging protocols, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.


June 10, 2021 — Diagnostic and Interventional Cardiology (DAIC) magazine has won a prestigious Jesse H. Neal Award for its COVID-19 coverage during 2020. DAIC won the award for Best Technical/Scientific Content for its entry "delivering Detailed Medical Information to Clinicians During COVID-19."



The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work together. That is the idea behind the Applied Health Innovation Consortium (AHIC) led by the American College of Cardiology (ACC).


June 9, 2021 — AI Med will present its Virtual Clinical Series: Imaging Built by Clinicians, for Clinicians, June 29-30, 2021. This is AI Med’s second CME-accredited, multi-track virtual track of 2021 and will bring together healthcare executives and clinicians specializing in cardiology, radiology, pathology, dermatology and ophthalmology.

AI Med Clinical Series: Imaging Built by Clinicians, for Clinicians

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of resources to bring the Lotus transcatheter aortic valve replacement (TAVR) device to the U.S. market. However, the vendor found the Lotus lagged so far behind the first-to-market TAVR valves (the Edwards Lifesciences Sapien and the Medtronic CoreValve) that it was not worth further investment and removed the Lotus from the market in November 2020.


Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 American College of Cardiology (ACC) scientific sessions. 


Subscribe Now